published in 2018 a systematic literature review and meta-regression analysis of data aimed to describe the performance of anti-nuclear antibody (ANA) for classifying SLE, with the purpose to consider if ANA justified a position as a mandatory entry criterion for SLE cohorts (38). The gene discussed is BTG3; the disease is systemic lupus erythematosus.